Research Article - Biomedical Research (2018) Volume 29, Issue 5
Clinical efficacy of low molecular heparin on unexplained recurrent spontaneous abortion
Objective: To study the clinical effect of low molecular heparin administered to patients with Unexplained Recurrent Spontaneous Abortion (URSA).
Methodology: A total of 120 URSA patients admitted to our hospital from October 2015 to September 2017 were taken as observation subjects. They were divided into two groups based on a random number table, that is, control group (n=60) and observation group (n=60). The patients in the control group were administered with progesterone and human chorionic gonadotropin, while the patients in the observation group were administered with low molecular heparin. The two groups were compared statistically in terms of pregnancy outcomes, incidence of complications in pregnancy, and incidence of adverse drug reactions.
Results: For the pregnancy outcomes, the pregnancy success rate of patients in the observation group is higher than that of the patients in the control group at 90.00% and 68.33%, respectively, indicating a significant difference (P<0.05). For the incidence of complications in pregnancy, the results of the patients in the observation group are lower than those of the patients in the control group at 90.00% and 68.33%, respectively, indicating a significant difference (P<0.05). In the incidence of adverse drug reactions, the results of the comparison between the patients in the observation group and those in the control group are at 20.00% and 23.33%, respectively, and no significant difference was observed (P>0.05).
Conclusion: Low molecular heparin administered to the URSA patients manifests a strong clinical effect. This treatment not only improves the pregnancy success rate but also reduces the incidence of complications. Furthermore, low molecular heparin is characterized by safety and reliability, and has potential for application in clinical studies.Author(s): Guang-Li Xu, Xiao-Fang Hu, Yong-Mei Han, Ai-Wu Wei